Is Broach Lifecare overvalued or undervalued?

As of 22 September 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.84, an EV to EBITDA ratio of 12.69, and a Price to Book Value of 1.27. These ratios suggest that the company is trading at a reasonable valuation compared to its earnings and book value.
In comparison to its peers, Broach Lifecare's PE ratio is significantly lower than that of Max Healthcare, which is considered very expensive at a PE of 94.6, and also lower than Apollo Hospitals, which has a PE of 70.79 but is rated attractive. This positions Broach Lifecare favorably within the industry, especially given its lower PEG ratio of 0.00, indicating potential for growth at a reasonable price. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -9.72% compared to the Sensex's 5.15%, the overall valuation metrics suggest that Broach Lifecare remains an attractive investment opportunity.